International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct

Study (n=91; median follow up 28 months) did not find a difference in objective response rate (57% vs 59%) but did note more serious adverse events (62% vs 36%; P = 0.016) and unfavourable survival benefit (12.3 vs 20 months) with cisplatin/fluorouracil vs carboplatin/paclitaxel.


Journal of Clinical Oncology